April 14, 2021
Business News

Galderma Announces Publication of Phase 2b Trial Results Demonstrating the Rapid and Long-lasting Benefits of Nemolizumab in Clinical Trial Subjects With Uncontrolled Atopic Dermatitis


LAUSANNE, Switzerland–()–Galderma today announced that the Journal of the European Academy of Dermatology and Venereology (JEADV) has published full results from a post-hoc analysis of the phase 2b study of its investigational therapy, nemolizumab, in adult patients with moderate-to-severe atopic dermatitis (MtS AD).2 Published online on March 12, results of the analyses show that nemolizumab led to rapid and sustained improvements in itch, sleep, and skin lesions in adult patients with uncontrolled MtS AD.2

The published analysis evaluated the efficacy of nemolizumab versus placebo in adult patients with MtS AD:2

  • Nemolizumab-treated patients experienced significant itch relief within 48 hours of treatment…



Click here to view the original article.

Related Posts

You might also like ...

Fraunhofer and Sinclair to Collaborate Towards Integrating Digital Radio Mondiale Framework into the ATSC 3.0 Digital TV Platform
Sopheon Bridges Gaps Between Digital and Physical Product Development with Launch of Accolade for Smart Products
Riassunto: Alkira collabora con Microsoft per trasformare il passaggio al cloud networking verso Azure